NTT-DOCOMO
20.1.2023 09:01:39 CET | Business Wire | Press release
NTT DOCOMO, INC. announced today that it will organize a full-scale booth at MWC Barcelona 2023, the world’s largest mobile-related exhibition, in Barcelona, Spain from February 27 to March 2.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230120005094/en/
NTT DOCOMO Booth at MWC Barcelona 2023 (Graphic: Business Wire)
The DOCOMO booth, which will showcase exhibitions and presentations focused on the main themes of 6G, open radio access networks (Open RAN) and extended reality (XR), will also promote international standardization and global business for next-generation communication technologies. Due to the global pandemic, this will be DOCOMO’s the first onsite appearance at MWC Barcelona since 2019.1
In the 6G section, DOCOMO will present the coming 6G world and advanced wireless technologies that the company is currently developing. This will include a demonstration of the Human Augmentation Platform to communicate haptic sensations between people connected to a 6G network to enable, for example, a musical student to mimic the exact finger motions of a teacher.
In the Open RAN section, DOCOMO will present experiential content to help visitors understand the concept and structure of Open RAN, as well as progress being achieved to enable multi-vendor telecommunication equipment2 to be combined in Open RAN, as well as related collaborations with international carriers.
In the XR section, visitors will experience the metaverse filled with music, anime and movies and also a virtual-live system, both provided by NTT QONOQ, INC., a company launched by DOCOMO’s parent NTT group last October to promote XR business.
Through this exhibition, DOCOMO looks forward to globally communicating its advanced technologies and businesses under the company’s brand slogan “changing worlds with you.”
For more about DOCOMO’s exhibits and the overall exhibition, please refer to the appendix.
1 DOCOMO organized an exhibition in Japan in 2021 and then one online in 2022.
2 Creation of 5G Open RAN Ecosystem to Accelerate Adoption of Open RAN by Operators Globally”
https://www.docomo.ne.jp/english/info/media_center/pr/2021/0208_00.html
About NTT DOCOMO
NTT DOCOMO, Japan's leading mobile operator with over 85 million subscriptions, is one of the world's foremost contributors to 3G, 4G and 5G mobile network technologies. Beyond core communications services, DOCOMO is challenging new frontiers in collaboration with a growing number of entities ("+d" partners), creating exciting and convenient value-added services that change the way people live and work. Under a medium-term plan toward 2020 and beyond, DOCOMO is pioneering a leading-edge 5G network to facilitate innovative services that will amaze and inspire customers beyond their expectations.
https://www.docomo.ne.jp/english/
Appendix
Overview of NTT DOCOMO Booth at MWC Barcelona 2023
1. Exhibitions
Theme |
Exhibits |
Contents |
6G |
Human Augmentation Platform |
As an example of this 6G application, presenters will use haptic information to teach musical techniques and guide a robot in whisking green tea. |
Wireless Technologies |
DOCOMO’s technical approaches to the realization of 6G will be introduced with detailed explanations. |
|
Open RAN |
Interactive Contents |
Experiential content in the form of a simulation game will allow visitors to grasp the overview and structure of Open RAN. |
Shared Open Lab
|
This Open RAN verification facility located at the DOCOMO R&D Center in Japan will be introduced in 3D. |
|
XR |
XR World |
This metaverse diorama will enable people to view a life-size Godzilla from various angles. |
Matrix Stream |
Presenting NTT QONOQ’s virtual-live and general-purpose video-delivery system for extended reality |
|
Mixed Reality Animals—Volumetric Video × Magic Leap 2 |
Videos of real cats and penguins will be converted to 3DCG and projected into real space using a Magic Leap 2 MR headset. |
2. NTT DOCOMO Booth Location
4E50, Hall 4
3. Presentations
1 |
Broadcast Stage
|
2 |
5G Futures Summit
|
Note: The content and schedule of the presentations are subject to change. Please check the official website of MWC Barcelona 2023 for the latest information.
Reference
MWC Barcelona 2023
1. Dates & Times
Monday, February 27 to Thursday, March 2
08:30 to 19:00, except last day from 08:30 to 16:00 (all times local)
2. Venue
Fira Gran Via
Av. Joan Carles I, 64
08908 L'Hospitalet de Llobregat
Barcelona, Spain
3. Official Website
https://www.mwcbarcelona.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230120005094/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom